News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
<Research>M Stanley Expects MINIMAX-W (00100.HK) Iteration Pace Accelerating; Rating Overweight
MINIMAX-W (00100.HK) launched its new generation Agent flagship large model, M2.7, yesterday, demonstrating that the Group's iteration pace is accelerating, as M2.7 was launche...
Reset
Send
The window will close in 5 seconds
<Research>M Stanley Expects MINIMAX-W (00100.HK) Iteration Pace Accelerating; Rating Overweight
Close
Recommend
34
Positive
49
Negative
47
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get NVDA share!

MINIMAX-W (00100.HK)  -110.500 (-10.425%)    Short selling $150.00M; Ratio 24.219%   launched its new generation Agent flagship large model, M2.7, yesterday, demonstrating that the Group's iteration pace is accelerating, as M2.7 was launched within a month after M2.5, Morgan Stanley released a research report saying.

The Company also revealed that, compared to M2.5, M2.7 achieved significant improvements in OpenClaw performance, reaching levels close to Sonnet4.6 in MMClaw benchmark tests.

Related News HSBC Research Lowers TP of SENSETIME (00020.HK) to HKD2, Focuses on AI Market Position Competition
Morgan Stanley also believed that the Group is likely to drive further token growth following OpenClaw. Therefore, the broker rated MINIMAX-W at Overweight, with a target price of $990, equivalent to a projected 2027 PS ratio of 56x.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-04-02 16:25.)

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.